BMO Capital analyst Keith Tapper lowered the firm’s price target on Neurogene (NGNE) to $45 from $60 but keeps an Outperform rating on the shares after its Q3 results. The stock is now trading “near cash” as the company disclosed a Serious Adverse Event in its NGN-401 high dose trial and the termination of Battens program that was announced on November 11, though the management does not expect a clinical hold after conversations with FDA, acknowledging safety of low-dose, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Neurogene Inc. Faces Uncertainty with NGN-101 Program Amid FDA Challenges and Strategic Hurdles
- Neurogene price target lowered to $45 from $60 at BMO Capital
- Neurogene price target lowered to $46 from $72 at Baird
- Neurogene selloff on safety event an overreaction, says H.C. Wainwright
- Closing Bell Movers: Super Micro up 28% on compliance update